Meeting
2022 ASCO Annual Meeting
PANOVA-3: A phase 3 study of tumor-treating fields with gemcitabine and nab-paclitaxel for frontline treatment of locally advanced pancreatic adenocarcinoma.
Authors
Vincent J. Picozzi
Virginia Mason Hospital and Medical Center, Seattle, WA
Vincent J. Picozzi , Teresa Macarulla , Philip Agop Philip , Carlos Roberto Becerra , Tomislav Dragovich
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT03377491
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS4187)
DOI
10.1200/JCO.2022.40.16_suppl.TPS4187
Abstract #
TPS4187
Poster Bd #
158b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
PANOVA-3: A phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic adenocarcinoma.
First Author: Vincent J. Picozzi
Poster
2021 Gastrointestinal Cancers Symposium
A phase III trial of tumor-treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC): PANOVA-3.
First Author: Vincent J. Picozzi
Poster
2020 Gastrointestinal Cancers Symposium
PANOVA-3: A phase III study of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma (LAPC).
First Author: Vincent J. Picozzi
Poster
2019 Gastrointestinal Cancers Symposium
PANOVA-3: A phase III study of tumor treating fields with nabpaclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC).
First Author: Uri Weinberg